News

Ophthalmology Times19h
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy
VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...
Ophthalmology Times19h
Oculis completes enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for DME eye drop candidate
Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.